Insiders Nkarta, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
6.3 ^USD	-1.56%		-16.33%	-4.55%

03-26	Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating	MT
03-25	HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating	MT

Nkarta Names Alyssa Levin as Chief Financial and Business Officer	05/07/23	MT
Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer	05/07/23	CI
Nkarta, Inc. Appoints Alyssa Levin as Chief Business Officer	05/07/23	CI
Laura Shawver Announces Not Stand for Re-Election to the Board of Nkarta, Inc	24/04/23	CI
Nkarta CFO Nadir Mahmood Resigns; Trial Update on Prospective Leukemia Treatment Set for Q2; Stock Rises	30/03/23	MT
Nkarta, Inc. Announces Resignation of Nadir Mahmood as Chief Financial and Business Officer	30/03/23	CI
Nkarta Names David Shook as Chief Medical Officer	09/01/23	MT
Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer	09/01/23	CI
Insider Sell: Nkarta	30/09/22	MT
Insider Sell: Nkarta	17/08/22	MT
Insider Sell: Nkarta	17/08/22	MT
Nkarta Appoints Chief Technical Officer, Chief Administrative Officer	25/07/22	MT
Nkarta, Inc. Announces Executive Changes	25/07/22	CI
Nkarta, Inc. Announces Executive Changes	16/05/22	CI
Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors	29/03/22	CI
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term	14/06/21	GL
Nkarta, Inc. Announces Executive Changes	05/10/20	CI
Nkarta, Inc. Announces Board Appointments	27/04/20	CI
Nkarta Therapeutics Appoints Yvonne Li as Senior Vice President, Finance	09/12/19	CI
Nkarta Therapeutics Promotes Nadir Mahmood to Chief Business Officer	18/09/19	CI

No results for this search